Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Canagliflozin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, Endothelial Cells, Cellular Biomarker, Endothelial Dysfunction, CD34+, Impaired renal function
Eligibility Criteria
Inclusion Criteria:
- Age 30-70 years
- Currently treated with any combination of the following anti-diabetic therapies: metformin (1-2 grams), insulin, GLP-1 agonists, a DPP-IV inhibitor, or sulfonylureas
- Hemoglobin A1C (HbA1C) between 7.0% and 10.0%
- Body Mass Index (BMI) between 25 and 39.9 kg/m^2 (both inclusive)
Exclusion Criteria:
- Type 1 diabetes
- History of hyperosmolar nonketotic coma
- History of diabetic ketoacidosis in the last 3 months
- Abnormal CBC that is judged by physician to be unsafe to enroll or low hematocrit (<28 UNITS).
- History of pancreatitis
- History of diabetic ketoacidosis in the last 3 months
- History of cancer (except basal cell carcinoma and cancer that is cured or not active or being treated in the past 5 years)
- Heart attack or stroke within 6 months of screening
- Clinically significant coronary and/or peripheral vascular disease that would be unsafe to enroll in the study.
- Statin use started or dose change in the last 3 months
- CKD Stages 3,4 and 5
- Use of oral or injectable anti-diabetic medication other than any combination of the following anti-diabetic therapies: metformin (1-2 grams), insulin, GLP-1 agonists, a DPP-IV inhibitor, or sulfonylureas currently, or in the past 1 month.
- Use of consistent long-term steroid medication (oral, inhaled, injected) within the last 3 months
- Uncontrolled inflammatory disease, or current chronic use of anti-inflammatory drugs within the last 3 months. **This will be judged on a case by case basis by the PI**
- Implanted devices (e.g., pacemakers) that may interact with Body Composition scale
- Untreated Systolic Blood Pressure > 150 mmHg and diastolic Blood Pressure > 90 mmHg
- Active wounds or recent surgery within 3 months
- Untreated hyper/hypothyroidism
Physical and Laboratory Test Findings:
- Pre-existing liver disease and/or ALT and AST >2.5X's UNL
- Serum creatinine levels ≥2.0
- Estimated CrCl < 60 mL/min (measured by eGFR value)
- Triglycerides >450 mg/dL
Allergies and Adverse Drug Reactions:
- Subjects with a history of any serious hypersensitivity reaction to Cana or another SGLT2 inhibitor.
Sex and Reproductive Status:
- Women in reproductive age group will be included in the study but encouraged to use contraceptive method to avoid pregnancy within 16 weeks of study duration.
- Women who are pregnant or breast-feeding will be excluded.
Other Exclusion Criteria:
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
- Patients who are active smokers
- Patients who are pregnant
- Nursing women
- Post-menopausal women who are on estrogen hormone replacement therapy will be excluded.
- Patients on low dose oral contraceptives will be allowed to participate as these formulations contain very low amounts of estrogens.
- Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and to ensure that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.
Sites / Locations
- The George Washington University Medical Faculty Associates
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Active Arm
Placebo Arm
Arm Description
100 mg of Canagliflozin for 16 weeks
Placebo for 16 weeks
Outcomes
Primary Outcome Measures
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Protein Expression)
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Percentages)
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Counts)
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation)
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Secondary Outcome Measures
Serum Endothelial Inflammatory Markers (1)
IL-6, and TNF-alpha
Fasting Lipid Profile
Measured from a serum blood Lipid Panel: cholesterol and serum ketone bodies
Glycemic Control (HbA1C)
As determined by HbA1C values
BMI
Determined as weight in kg divided by height in meters squared
Resting Metabolic Rate (RMR)
Using ReeVue (trademark) machine, with or without SGLT2 inhibitor therapy to ascertain if Cana has any effect on RMR. Other related trials have shown weight loss but effect on metabolic rate has not been studied .
Pulse Wave Velocity
Vessel health assessed by using arterial tonometry with the SphygmoCor CP system from ATCOR .
Serum Endothelial Inflammatory Markers (2)
Highly selective C-reactive protein (hs-CRP)
Glycemic Control
Measured from blood glucose values (fasting) during visit
Body Fat Percentage
Measured using a Tanita body composition scale
Augmentation Index (Pulse Wave Analysis)
Vessel health assessed by using arterial tonometry with the SphygmoCor CP system from ATCOR. Higher values generally correlate with increased cardiovascular risk.
Kidney Function Markers
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Creatinine (Urine)
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Microalbumin
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
eGFR
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Full Information
NCT ID
NCT02964585
First Posted
October 6, 2016
Last Updated
November 10, 2022
Sponsor
George Washington University
Collaborators
Janssen Scientific Affairs, LLC
1. Study Identification
Unique Protocol Identification Number
NCT02964585
Brief Title
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
Official Title
Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
January 2020 (Actual)
Study Completion Date
September 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
George Washington University
Collaborators
Janssen Scientific Affairs, LLC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction.
Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.
Detailed Description
Diabetes affects more than 11% of adults in the United States and this is projected to nearly double by 2025. Both diabetes and obesity are associated with endothelial dysfunction, oxidative stress, endothelial cell inflammation, cardiovascular pro-thrombotic states and are the most common causes of kidney disease. Use of a sodium-glucose linked transporter (SGLT-2) inhibitor has shown promise in improving glycemic control, weight reduction, hypertension and even changes in circulating Renin-angiotensin-aldosterone system (RAAS) and nitric oxide (NO). However, whether these group of drugs have any effect on cardiovascular disease (CVD) risk modification or on endothelium or endothelial progenitor cells as a surrogate of cardiovascular and renal risk outcome measure, is unclear.
The investigators have previously shown that CD34+ cells, derived from peripheral blood can act as a cellular biomarker that is more reliable than serum based markers for CVD risk estimation. Serum based inflammatory markers are not useful until the endothelium is already damaged and inflamed. Such serum based biomarkers takes several months to change and gives no preventive and predictable information as to whether a particular medication may affect future endothelium. This is why the study of endothelium progenitors is crucial. In the investigators' previous study of a prediabetes population with an aerobic exercise intervention, the investigators have demonstrated that CD34+ cells are responsive to a change in therapy or intervention within 2-4 weeks and can be used as a reliable non serum based cellular bio-marker. CD34+ cells or endothelial progenitor cells have been used clinically to improve collateral circulation and have been extensively studied as a robust cardiovascular biomarker. Therefore studying CD34+ cells in patients, with or without Canagliflozin (Cana) can give vital information about the medication and its effect on endothelium. This is particularly important as another SGLT2 inhibitor Empagliflozin has shown unparalleled positive cardiovascular effects with an oral hypoglycemic agent. Of course, the question arises whether this clinical trial effect is secondary to glucose effect or direct effect of SGLT2 inhibitor on endothelium.
Multiple glucose transporters have been identified in human cells these include GLUTs, SGLTs and even taste receptors (such as TLR2 and TLR3). The investigators know SGLT transporters are present in tubular cells and clearly blocking of SGLT2 in these cells is beneficial. Information on glucose transporter in stem or progenitor cells is almost nil. In our lab the investigators have shown presence of GLUT1, SGLTs and TLR3 on CD34+ cells. The investigators have also demonstrated that hyperglycemia is toxic to CD34+ cells, more than CD31+ positive mature endothelial cells. The investigators hypothesize that blocking SGLT2 in CD34+ cells will be beneficial rather than detrimental. As far as glucose uptake in CD34+ cells are concerned other glucose transporters should be sufficient, in fact lesser amount of glucose entry in a hyperglycemic milieu (type 2 DM patients) may be less pro-inflammatory and less pro-apoptotic.
Our preliminary data indicates that mRNA gene expression of both SGLT1 and SGLT2 are noted on human CD34+ cells however only SGLT2 mRNA gene expression is up-regulated several fold in human CD34+ cells in presence of hyperglycemia (20mM glucose). However non primary commercially obtained human endothelium (HUVEC) do not show similar results. An explanation could be SGLT2 expression decreases as the cell transitions from progenitor to mature endothelium. From these results the investigators believe SGLT2 inhibitor will be effective on progenitors and not mature endothelium. The investigators therefore hypothesize that CD34+ cells will be an ideal biomarker to study the effect of the drug. It is possible that Cana, by blocking SGLT2 receptors, may influence other CD34+ cell surface receptors including other glucose transporters and influence its function (most importantly migration). If a particular medication positively influences stem/progenitor cell migration then that medication can positively influence endothelial dysfunction and vascular complications from diabetes. The investigators are particularly interested to note effect of Canagliflozin, a SGLT2 inhibitor on other glucose transporters such as GLUT 1 and 4 while looking at SGLT 1 and 2 on CD34+ cells. It will be helpful to discern these effects particularly when choice of oral diabetic medication in a type 2 diabetes population is practically limited to metformin, DPP4 inhibitors and SGLT2 inhibitors. The investigators plan to investigate the effect of Cana on CD34+ cells, in a placebo matched study. The investigators plan to recruit subjects with type 2 diabetes with the following characteristics: 1) overweight, mild and moderately obese (BMI=25.0-39.9); 2) individuals with early type 2 diabetes (≤15 years) with inadequate control, HbA1C= 7.0 to 10.0%, on Metformin (1-2 grams/day) 3) with no history or presence of macrovascular complication and CKD no higher than stage 2. The subjects will be on Metformin as per ADA, Metformin is the 1st line of care along with life-style modification. While Metformin on its own may affect inflammatory biomarkers, the effect is minimal at best, particularly in presence of CKD and endothelial dysfunction. Also both placebo and the cana group will be on Metformin.
The investigators will recruit a total of 40 patients (20 individuals/per group) with approximately a 20% drop out rate over two years and the investigators hope to retain 32 individuals (16/group). Individuals in each group will be matched by sex, age, and race. Participants will be assessed at baseline (week 0), and at 2 and 4 months of drug intake.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus, Endothelial Cells, Cellular Biomarker, Endothelial Dysfunction, CD34+, Impaired renal function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active Arm
Arm Type
Active Comparator
Arm Description
100 mg of Canagliflozin for 16 weeks
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
Placebo for 16 weeks
Intervention Type
Drug
Intervention Name(s)
Canagliflozin
Other Intervention Name(s)
INVOKANA
Intervention Description
100 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
1 tablet daily for 16 weeks
Primary Outcome Measure Information:
Title
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Protein Expression)
Description
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Percentages)
Description
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Counts)
Description
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation)
Description
To determine whether 4 months of Canagliflozin modifies CD34+ cell number, gene expression and migration function. The investigators will obtain a total of approximately 95 mL of peripheral blood per visit. Of these 95 mL, 60-70 mL will be used to obtain CD34+ cells from mononuclear cell (MNC) population and 25-35 mL for biochemistry and plasma ELISA assays. MNC will be obtained from whole blood similar to protocols described before [13,14]. MNCs will be put through CD34 magnetic bead column to obtain CD34+ cells (Miltenyi Biotec). Purity of CD34+ cells, post sort, usually is above 90%, to be verified by FACS analysis.
Time Frame
16 weeks post Canagliflozin treatment reported
Secondary Outcome Measure Information:
Title
Serum Endothelial Inflammatory Markers (1)
Description
IL-6, and TNF-alpha
Time Frame
measured at 8 and 16 (reported) weeks post treatment
Title
Fasting Lipid Profile
Description
Measured from a serum blood Lipid Panel: cholesterol and serum ketone bodies
Time Frame
16 weeks post Canagliflozin treatment reported (also measured at 8 weeks)
Title
Glycemic Control (HbA1C)
Description
As determined by HbA1C values
Time Frame
16 weeks post Canagliflozin treatment reported
Title
BMI
Description
Determined as weight in kg divided by height in meters squared
Time Frame
16 weeks post Canagliflozin treatment
Title
Resting Metabolic Rate (RMR)
Description
Using ReeVue (trademark) machine, with or without SGLT2 inhibitor therapy to ascertain if Cana has any effect on RMR. Other related trials have shown weight loss but effect on metabolic rate has not been studied .
Time Frame
16 weeks post Canagliflozin treatment
Title
Pulse Wave Velocity
Description
Vessel health assessed by using arterial tonometry with the SphygmoCor CP system from ATCOR .
Time Frame
16 weeks post Canagliflozin treatment reported (also measured at 8 weeks)
Title
Serum Endothelial Inflammatory Markers (2)
Description
Highly selective C-reactive protein (hs-CRP)
Time Frame
measured at 8 and 16 (reported) weeks post treatment
Title
Glycemic Control
Description
Measured from blood glucose values (fasting) during visit
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Body Fat Percentage
Description
Measured using a Tanita body composition scale
Time Frame
16 weeks post Canagliflozin treatment
Title
Augmentation Index (Pulse Wave Analysis)
Description
Vessel health assessed by using arterial tonometry with the SphygmoCor CP system from ATCOR. Higher values generally correlate with increased cardiovascular risk.
Time Frame
16 weeks post Canagliflozin treatment reported (also measured at 8 weeks)
Title
Kidney Function Markers
Description
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Creatinine (Urine)
Description
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Time Frame
16 weeks post Canagliflozin treatment reported
Title
Microalbumin
Description
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Time Frame
16 weeks post Canagliflozin treatment reported
Title
eGFR
Description
Creatinine Clearance and Kidney Function measured from compiled results from a urine sample and blood tests
Time Frame
16 weeks post Canagliflozin treatment reported
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 30-70 years
Currently treated with any combination of the following anti-diabetic therapies: metformin (1-2 grams), insulin, GLP-1 agonists, a DPP-IV inhibitor, or sulfonylureas
Hemoglobin A1C (HbA1C) between 7.0% and 10.0%
Body Mass Index (BMI) between 25 and 39.9 kg/m^2 (both inclusive)
Exclusion Criteria:
Type 1 diabetes
History of hyperosmolar nonketotic coma
History of diabetic ketoacidosis in the last 3 months
Abnormal CBC that is judged by physician to be unsafe to enroll or low hematocrit (<28 UNITS).
History of pancreatitis
History of diabetic ketoacidosis in the last 3 months
History of cancer (except basal cell carcinoma and cancer that is cured or not active or being treated in the past 5 years)
Heart attack or stroke within 6 months of screening
Clinically significant coronary and/or peripheral vascular disease that would be unsafe to enroll in the study.
Statin use started or dose change in the last 3 months
CKD Stages 3,4 and 5
Use of oral or injectable anti-diabetic medication other than any combination of the following anti-diabetic therapies: metformin (1-2 grams), insulin, GLP-1 agonists, a DPP-IV inhibitor, or sulfonylureas currently, or in the past 1 month.
Use of consistent long-term steroid medication (oral, inhaled, injected) within the last 3 months
Uncontrolled inflammatory disease, or current chronic use of anti-inflammatory drugs within the last 3 months. **This will be judged on a case by case basis by the PI**
Implanted devices (e.g., pacemakers) that may interact with Body Composition scale
Untreated Systolic Blood Pressure > 150 mmHg and diastolic Blood Pressure > 90 mmHg
Active wounds or recent surgery within 3 months
Untreated hyper/hypothyroidism
Physical and Laboratory Test Findings:
Pre-existing liver disease and/or ALT and AST >2.5X's UNL
Serum creatinine levels ≥2.0
Estimated CrCl < 60 mL/min (measured by eGFR value)
Triglycerides >450 mg/dL
Allergies and Adverse Drug Reactions:
Subjects with a history of any serious hypersensitivity reaction to Cana or another SGLT2 inhibitor.
Sex and Reproductive Status:
Women in reproductive age group will be included in the study but encouraged to use contraceptive method to avoid pregnancy within 16 weeks of study duration.
Women who are pregnant or breast-feeding will be excluded.
Other Exclusion Criteria:
Prisoners or subjects who are involuntarily incarcerated.
Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
Patients who are active smokers
Patients who are pregnant
Nursing women
Post-menopausal women who are on estrogen hormone replacement therapy will be excluded.
Patients on low dose oral contraceptives will be allowed to participate as these formulations contain very low amounts of estrogens.
Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and to ensure that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sabyasachi Sen, MD, PhD
Organizational Affiliation
Medical Faculty Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
The George Washington University Medical Faculty Associates
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
16028691
Citation
Sen S, Strappe PM, O'Brien T. Gene transfer in endothelial dysfunction and hypertension. Methods Mol Med. 2005;108:299-314. doi: 10.1385/1-59259-850-1:299.
Results Reference
background
PubMed Identifier
19339628
Citation
Krenning G, Dankers PY, Drouven JW, Waanders F, Franssen CF, van Luyn MJ, Harmsen MC, Popa ER. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1314-22. doi: 10.1152/ajprenal.90755.2008. Epub 2009 Apr 1.
Results Reference
background
Citation
Department of Health and Human Services, NIH and National Center for Chronic Disease Prevention and Health Promotion, "National Diabetes Statistics: 2007 and 2011 Fact Sheet." 2011
Results Reference
background
PubMed Identifier
24357209
Citation
American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014. No abstract available.
Results Reference
background
PubMed Identifier
23362314
Citation
Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013 Feb;24(2):302-8. doi: 10.1681/ASN.2012070718. Epub 2013 Jan 29.
Results Reference
background
PubMed Identifier
17179929
Citation
Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007 Jan;3(1):46-56. doi: 10.1038/ncpendmet0366.
Results Reference
background
PubMed Identifier
24334174
Citation
Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014 Feb 4;129(5):542-4. doi: 10.1161/CIRCULATIONAHA.113.007071. Epub 2013 Dec 13. No abstract available.
Results Reference
background
PubMed Identifier
24631482
Citation
Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May;8(5):330-9. doi: 10.1016/j.jash.2014.02.003. Epub 2014 Feb 12.
Results Reference
background
Citation
Sabyasachi Sen, Sarah Witkowski, Ann Lagoy, Ashequl M. Islam: A six-week home exercise program improves endothelial function and CD34+ circulating progenitor cells in patients with pre-diabetes. J Endocrinol Metab.2015; 5 (1-2):163-171, doi: http://dx.doi.org/10.14740/jem273w.
Results Reference
background
PubMed Identifier
16148285
Citation
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005 Sep 8;353(10):999-1007. doi: 10.1056/NEJMoa043814.
Results Reference
background
PubMed Identifier
17562958
Citation
Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007 Jun 26;115(25):3165-72. doi: 10.1161/CIRCULATIONAHA.106.687376. Epub 2007 Jun 11.
Results Reference
background
PubMed Identifier
26378978
Citation
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Results Reference
background
PubMed Identifier
33581737
Citation
Nandula SR, Kundu N, Awal HB, Brichacek B, Fakhri M, Aimalla N, Elzarki A, Amdur RL, Sen S. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes. Cardiovasc Diabetol. 2021 Feb 13;20(1):44. doi: 10.1186/s12933-021-01235-4.
Results Reference
result
Learn more about this trial
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs